Evidence map›Paper›PMID 26285604›Full record

ArticleInternational journal of obesity (2005)2016

Association of metabolic parameters and rs726344 in FNDC5 with serum irisin concentrations.

T Ebert, S Kralisch, U Wurst, M Scholz, M Stumvoll, P Kovacs, M Fasshauer, A Tönjes

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of obesity (2005), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

T EbertDepartment of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany.ORCID http://orcid.org/0000-0003-1683-9276
S KralischDepartment of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany.
U WurstDepartment of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany.
M ScholzInstitute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
M StumvollDepartment of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany.
P KovacsLeipzig University Medical Center, IFB AdiposityDiseases, Leipzig, Germany.
M FasshauerDepartment of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany.
A TönjesDepartment of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany.
IFB Adiposity Diseases · DELeipzig University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesIrisin has been suggested as a novel myokine with beneficial effects in rodents. However, previous data in humans showed conflicting results regarding its association with metabolic phenotypes and regulation of secretion. Furthermore, although an association of rs726344 in FNDC5 (fibronectin type III domain containing 5) coding for irisin with insulin sensitivity was reported, the effects of genetic variation at this locus on irisin serum levels have not been investigated, so far. Therefore, we investigated circulating irisin and the associations with rs726344 in a cohort of >1000 subjects. SUBJECTS/

methodsIrisin serum concentrations were measured with enzyme-linked immunosorbent assay. Associations with metabolic parameters including renal function, glucose and lipid metabolism, inflammation, as well as adipokine profiles, were assessed in regression models. Dynamic changes of serum irisin were investigated during oral glucose tolerance test (OGTT) in a subset of the cohort (n=136). rs726344 was genotyped in all subjects and analyzed for associations with serum irisin and traits of the metabolic syndrome.

resultsIrisin was negatively associated with fat mass, fasting glucose and dyslipidemia but not with other adipokines. Moreover, irisin decreased during an OGTT in a subcohort comprising subjects with normal glucose tolerance, impaired fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus. rs726344 was not associated with serum irisin levels or with other anthropometric and biochemical parameters.

conclusionsCirculating irisin levels are associated with a beneficial metabolic profile but not with other adipokines and not with rs726344 in our cohort. Our data suggest a potential favorable role of irisin in the regulation of metabolism.

Indexed as

AdultBlood GlucoseBody Fat DistributionEnzyme-Linked Immunosorbent AssayFemaleFibronectinsGene Expression RegulationGene FrequencyGenetic Predisposition to DiseaseGermanyHumansInsulin ResistanceMaleMetabolic SyndromeMiddle AgedReproducibility of ResultsBlood GlucoseFibronectinsFNDC5 protein, human

Identifiers

PMID26285604
OpenAlexW1193456364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.